Lu X et al. - Early aggressive immunosuppressive therapy (within 2 weeks of onset of myelopathy) tend to associate with a favourable outcome. Methods
Study to evaluate the factors that contribute to Myelopathy in SLE
14 pts with lupus myelopathy (LM) were retrospectively studied
Another 23 pts with other neuropsychiatric SLE (NPSLE) features were enrolled as a comparison group
The morbidity of LM was evaluated by the ASIA Impairment Scale
The clinical and serological characteristics and prognostic factors for LM were investigated
Results
The age, gender, duration of SLE, non-CNS disease activity and autoantibody profile in pts with LM was not different in the NPSLE cohort
A relatively low prevalence of anti–phospholipid antibodies in LM sera vs NPSLE was observed
Longitudinal lesion detected by MRI was identified in 33.3% of pts with LM, whereas 50% showed focal speckle-like lesions
The morbidity of LM was 50%
Muscle strength of grade 3 or higher on admission was a strong indicator for a better prognosis
Whereas other parameters including longitudinal lesion, sensory deficit level, disease activity and αPL did not discriminate good from poor outcome in LM
See all
